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Atrial ﬁbrillation (AF) is associated with a 3-to-5 fold increased risk
ischaemic stroke (Ball et al., 2013). AF often occurs in association with
other cardiac problems, such as chronic heart failure (up to 50% develop
AF) and Acute Coronary Syndrome (up to 25% develop AF) leading to
worse outcomes (Ball et al., 2013). Appropriate thromboprophylaxis is
central for prevention of thrombotic complications, but it can cause to
worrying complications, such as bleeding (Camm et al., 2012a;
Kirchhof et al., 2011). (See Fig. 1.)
The risks associated with AF are not homogeneous, and various risk
factors for stroke and bleeding have been identiﬁed, leading to the de-
velopment and validation of several stroke Risk Stratiﬁcation Models
(RSM). Recognition of the importance of establishing individual risk
proﬁles was accompanied by pursuing an integrative approach in risk
assessment with evaluation of ‘net clinical beneﬁt’ for the proposed
stratiﬁcation models (Pisters et al., 2012).
Currently proposed models particularly focus on non-valvular AF,
themost common type of AF, which is not related to haemodynamically
signiﬁcant rheumatic valvular disease (predominantly mitral stenosis)
or prosthetic heart valves (Camm et al., 2010).
2. Risk Factors for Stroke in Atrial Fibrillation: A Brief Overview
The pathophysiology of thromboembolism in AF is multi-factorial.
Increasing evidence points to the fulﬁlment of Virchow's triad. The
loss of atrial systole in AF results in increased stasis of blood within
the left atrium (blood ﬂow abnormalities). At macroscopic level, left
atrium and left atrium appendage enlargement are common ﬁndings
in AF. Inﬂammatory changes in atrial tissue have been demonstrated
at microscopic and molecular levels. The ﬁnal part of the Virchow's
triad, abnormal procoagulant blood constituents, is well recognised in
AF with abnormalities of coagulation and ﬁbrinolysis pathway resulting
to a chronic hypercoagulable state (Choudhury and Lip, 2004).
The most common risk factors associated with stroke (eg, heart fail-
ure, hypertension, diabetes, age, prior stroke) were initially identiﬁed
from treatment naïve cohorts of randomised trials conducted 2 decades
ago (Lip & Lane, 2015a). These trials only randomised b10% of patients
screened and many common stroke risk factors were not recorded or
consistently deﬁned.
A systematic analysis from the Stroke in AFWorkingGroup searched
for independent risk factors for stroke related to AF using information
from 27 studies. Of the 24 studies (although many were from trial co-
horts), age was found to be an independent risk of stroke, associated
with an incremental increase in risk of 1.5-fold per decade [Relative
Risk (RR) 1.5 per decade; 95% Conﬁdence Interval (CI), 1.3–1.7]. Overall
stroke risk increased 2.5-fold in patients with prior stroke/TIA (RR 2.5;
95% CI, 1.8–3.5). Hypertension was independently associated with
stroke in 13 of 20 studies (RR, 2.0; 95% CI, 1.6–2.5) (Pisters et al.,
2012). In another systematic review, history of hypertension was pres-
ent in 42% to 53% (mean of 48%) of analysed subjects and was indepen-
dently related to stroke in all studies included. Diabetes mellitus was
present in 14% to 18% (mean of 15%) of the study cohorts and it was a
signiﬁcant independent risk factor for stroke (RR 1.7, 95% CI, 1.4 to
2.0) (Fibrillation and Group, 2007). Interestingly, heart failure (HF)
and coronary artery disease did not emerge as independent predictors
for stroke risk in this analysis.Other data suggest that recent decompensated HF is indeed relat-
ed to higher risk of stroke in AF, whether left ventricular (LV) ejec-
tion fraction (EF) was reduced or preserved (Banerjee et al., 2012a;
Banerjee et al., 2013). However, moderate-to-severe systolic LV dys-
function on cardiac imaging is associated with a higher stroke risk
even if asymptomatic (Predictors of thromboembolism in atrial
ﬁbrillation, 1992; Wagstaff et al., 2014). One systematic review
found that although moderate–severe LV systolic impairment on
echocardiography is an independent risk factor for stroke/systemic
embolism, the magnitude by which it increases the risk of stroke
cannot be precisely quantiﬁed. Overall, although a clinical diagnosis
of HF have not been universally predictive of stroke in AF, signiﬁcant
impairment of LV contractility or previous admission due to HF de-
compensation irrespective of LV systolic function clearly increases
risk of stroke (Agarwal et al., 2014).
Female sex was also associated with an increased risk of stroke, es-
pecially in women aged N65 or in presence of an additional stroke risk
factor. Meta-analysis of 17 studies revealed a 1.31-fold (95% CIs) elevat-
ed risk of stroke in women with AF; especially in those aged ≥75 years
(Wagstaff et al., 2014). Overall, female sex plays limited role in prognos-
tication in AF at age of b65 years when there no other risk factors
(i.e., risk of ischaemic stroke b1%/year) (Melgaard et al., 2014; Friberg
et al., 2012a; Mikkelsen et al., 2012).
A systematic reviewbyAnandasundaramet al. supports a signiﬁcant
association between a history of myocardial infarction (MI) and the risk
of thromboembolism in AF (in 5 of 6 studies). Angina was reported as a
stroke risk factor in AF by two studies (Anandasundaram et al., 2013).
Furthermore, the presence of AF in association with peripheral artery
disease (PAD) and presence of complex plaque in the descending
aorta are independent predictors for stroke and thromboembolism in
AF (Zabalgoitia et al., 1998).
Renal failure has been assessed as a risk factor for stroke in AF pa-
tients. A correlation between decreasing glomerular ﬁltration rate and
stroke risk in conjunction with proteinuria has been reported as an in-
dependent stroke risk factor (Olesen et al., 2012). The Swedish Atrial Fi-
brillation cohort study conﬁrmed such association using the composite
endpoint, that included unspeciﬁed stroke, TIA and systemic embolism
but not with ischaemic stroke alone (Friberg et al., 2012b).
Standard echocardiography contributes to reﬁnement of stroke risk
stratiﬁcation.Moderate–severe LVdysfunction from2-D echocardiogra-
phywas the strongest independent predictor of later thromboembolism
(The Stroke Prevention in Atrial Fibrillation Investigators, 1992). LV hy-
pertrophy, deﬁned as a LVmass N 110 g/m2 inwomen and N134 g/m2 in
men, was found to be a signiﬁcant independent risk factor for stroke in
two studies (Pisters et al., 2012). Non-unexpectedly, demonstration of
left atrial thrombi, complex aortic plaque, spontaneous echo contrast
or low velocities in left atrial appendage have also been associated
with an increased risk of thromboembolism in AF (Zabalgoitia et al.,
1998).
Various blood-based biomarkers have been proposed to further
reﬁne estimation of stroke risk. High levels of ﬁbrin, D-dimer and
von Willebrand factor may identify AF patients at higher risk for
stroke in non-anticoagulated AF (Wannamethee et al., 2012; Lip
et al., 1996). Elevation in troponin I and NT-proBNP are common in
patients with AF and they are independently related to increased
risks of stroke and mortality even in anticoagulated patients (Hijazi
et al., 2012).
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Co-existence of several risk factors for stroke potentiates the overall
risk thus prompting development of various Risk Stratiﬁcation Models
(RSMs). Someof thesemodels categorise AF patients into ‘high’, ‘moder-
ate’, and ‘low’ risk strata; however, stroke risk is a continuumof risk, and
thus approaches based on risk quantiﬁcation appear the preferred op-
tion (Camm et al., 2010).
In 2001, an amalgamation of the AF Investigators (AFI) and Stroke
Prevention in AF (SPAF) schemes from the original historical trials led
to introduction of the CHADS2 score (Gage et al., 2001). The CHADS2 ac-
ronym was derived from the individual stroke risk factors: Congestive
heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, and
prior Stroke or TIA. Two points were given for prior stroke or TIA
(hence, the subscripted “2”), and 1 point was assigned for each of the
other factors (Gage et al., 2004).
The CHA2DS2-VASc score (Table 5) extends strokeprognostication in
AF by including additional common stroke predictors to the older
CHADS2 score (ages 65–74, vascular disease, and female sex) (Lip,
2015). The CHA2DS2-VASc score particularly improves the risk predic-
tion in many patients deemed ‘low risk’ based on the CHADS2 schema
(Table 1) (Olesen et al., 2011a; Lip, 2010). The CHA2DS2-VASc tool has
been validated in multiple independent populations and is now recom-
mended by the European (Camm et al., 2010), US (January et al., 2014)
and UK (NICE) (Atrial ﬁbrillation: management | Guidance and guide-
lines | NICE, 2015) guidelines.
Other risk stratiﬁcation schemes that have been developed, such as
the ATRIA (Singer et al., 2013) and the QSTROKE (Hippisley-Cox et al.,
2013), have included further clinical and/or demographic factors, as
well as different weighing strategies for primary or secondary preven-
tion of stroke. However, perceivedmarginal beneﬁts (at least statistical-
ly) of these scores are outweighed by their complexity and thus limited
practicality for everyday use. All suggested risk stratiﬁcation schemes
have their own limitations but the major guidelines emphasise the
role of CHA2DS2-VASc score for clinical use, in view of its better capabil-
ity to identify patients with genuinely low risk who do not need any an-
tithrombotic therapy along with ability to accurately quantify risk of
stroke in subjectswithmultiple risk factor and additional circumstances
needed to be considered decision making on individual based (e.g., risk
of bleeding) (Lip & Lane, 2015a).
4. Risk of Bleeding
Despite the clinical beneﬁt of OAC for stroke prevention in AF, major
bleeding events (especially intra-cranial bleeds) may be devastating
events. Identiﬁcation of patients at high risk of bleeding and delineation
of conditions and situations associatedwith bleeding risk can help to re-
ﬁne antithrombotic therapy in individual cases to minimise bleeding
risk (Lip et al., 2011).
The ﬁrst bleeding risk prediction score (ORBI score) was published
in 1998 and it was developed in patients newly started on warfarin
after hospitalisation for venous thromboembolism (Beyth et al., 1998).
Since then various bleeding risk scores have been described but only
four (HAEMORR2AGES (Gage et al., 2006), HAS-BLED (Pisters et al.,
2010), ATRIA (Fang et al., 2011) and ORBIT (O'Brien et al., 2015))
were developed and veriﬁed in AF populations.
The HAS-BLED score (Table 5) demonstrated good discriminatory
performance for “any clinically relevant bleeding” in anticoagulated pa-
tients with AF (Apostolakis et al., 2013a). It also performs well in
predicting bleeding events compared with older bleeding scores and
the ATRIA score (Apostolakis et al., 2013b). Other scores such as ATRIA
or ORBIT may falsely categorise some patients as “low risk’ with no ac-
tion needed whilst the HAS-BLED score would ﬂag up those subjects,
particularly if labile INRs are evident (Lip & Lane, 2015b).
Additionally, the simple HAS-BLED score was highly predictive of
bleeding events in patients manages with non-vitamin K oralanticoagulants (NOACs) (Apostolakis et al., 2013c), patients on triple
antithrombotic therapy post PCI (i.e., dual anti-platelets therapy and
warfarin) (Smith et al., 2012) and during bridging of chronic oral antico-
agulants with unfractionated or low molecular weight heparin prior to
surgery (Omran et al., 2012).
A HAS-BLED score ≥ 3 indicates high risk of bleeding and suggest
some caution with OAC in such patients with their regular review fol-
lowing the initiation of antithrombotic therapy (Camm et al., 2010). A
high HAS-BLED score is not a reason to withhold anticoagulation but it
emphasises the need to correct potential causes of bleeding such as un-
controlled hypertension, concomitant use of other medications that can
contribute to bleeding and falls, excessive alcohol consumption, etc. (Lip
& Lane, 2015a).
A large number of patientswith high risk of stroke/SE (i.e., CHA2DS2-
VASc Score N 3) also have a high risk of bleeding (Roldán et al., 2013).
This is partly due to the fact that both scores have some characteristics
in common (e.g., age, hypertension and previous stroke). Nonetheless,
HAS-BLED outperforms CHADS2 and CHA2DS2-VASc for predicting
bleeding (Apostolakis et al., 2013a). Thus, a bleeding risk score (HAS-
BLED) should be used to predict bleeding, and stroke risk assessed
using a speciﬁc stroke risk score (CHA2DS2-VASc) (Roldán et al.,
2013). From a large observational study the adjusted net clinical beneﬁt
favoured OAC in patients irrespective of HAS-BLED or CHA2DS2-VASc
score (Friberg et al., 2012c).
Many clinicians are reluctant to initiate appropriate antithrombotic
therapy in patients with AF and risk or history of falls. In a large “real
world” cohort, prior history of falls was uncommon and it was indepen-
dently associated with increased risk of stroke/thromboembolism,
bleeding, and mortality but not with haemorrhagic stroke in the pres-
ence of anticoagulation (Banerjee et al., 2014). In another cohort, pa-
tients on oral anticoagulants at high risk of falls did not have any
signiﬁcant increase in risk of major bleeds, and risk of falls is usually
not a valid reason to avoid OACs in AF patients (Donzé et al., 2012). In
a modelling analysis, Man-Son-Hing et al. estimated that elderly pa-
tients need to fall 295 times per year for the beneﬁt of stroke reduction
to be outweighed by serious bleeding (Man-Son-Hing et al., 1999).
5. Guidelines for Thromboprophylaxis in Atrial Fibrillation
The European Society of Cardiology (ESC) in 2010 (Camm et al.,
2010) with an update in 2012 (Camm et al., 2012a), the American Col-
lege of Chest Physicians (ACCP) in 2012 (You et al., 2012), the American
Heart Association/American College of Cardiology/Heart Rhythm Socie-
ty (AHA/ACC/HRS) in 2014 (January et al., 2014), the Canadian Cardio-
vascular Society (CCS) in 2014 (Verma et al., 2014) and the National
Institute for Health and Care Excellence (NICE) in 2014 (Atrial
ﬁbrillation: management | Guidance and guidelines | NICE, 2015) pub-
lished their guidelines for the management of stroke prevention in AF.
Table 2 provides a summary of the guidelines regarding the antithrom-
botic treatment for patients with NVAF.
5.1. Vitamin K Antagonists
Effective stroke prevention for patients with AF requires the use of
OACs, whether a VKA or a NOAC. The commonly used VKAs are 4-
hydroxycoumarins and include warfarin, phenprocoumon and
acenocoumarol (De Caterina et al., 2013). In six trials involving 2900 pa-
tients with a total of 186 strokes, anticoagulation with the VKAs was
compared with placebo or control. Meta-analysis showed that therapy
with adjusted dose warfarin reduced the relative risk for stroke by
64% (95% CI, 49% to 74%). All-cause mortality decreased in participants
who received warfarin compared to placebo/control [RR 26% (CI, 3% to
43%)] (Hart et al., 2007).
The prothrombin time assay has been used for decades to monitor
the intensity of therapy. To promote standardisation, the World Health
Organization introduced a prothrombin time standardisation expressed
Fig. 1. Algorithm for risk stratiﬁcation and selection of anticoagulation therapy for stroke prevention in atrial ﬁbrillation. Abbreviations: CHA2DS2-VASc: C, congestive heart failure, H,
hypertension, A2,age at least 75 years (×2), D, diabetes, S2, previous stroke, TIA, or systemic embolism, V, vascular disease,(×2) A, age 65 through 74 years, Sc, sex category female sex. HAS-
BLED: H, hypertension, A, abnormal renal and liver function, S, stroke, B, bleeding tendency, L, labile INRs, E, elderly, D, drugs. SAMe-TT2R2: S, sex (female), A, age (b60 y), Me, medical
history, T, treatment (interacting drugs), T2, tobacco use (×2), R2, race (not white)(×2). TTR, time in therapeutic range. VKA: vitamin K antagonists. NOAC: Non-vitamin K oral anticoagulant.
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2013). Suboptimal anticoagulation with frequent episodes of INR b 2.0
is a cause of many cases of thromboembolism, while those with an
INR N 3.0 make up many of the cases of major haemorrhage (Mearns
et al., 2014). Numerous studies have shown that an estimated time
spent in the therapeutic INR range (TTR) to be an important determi-
nant of the quality of anticoagulationwith VKA and risk of on treatment
thrombotic events (Mearns et al., 2014). TTR was also an independent
risk factor for major bleeding following initiation of VKA therapy
(Gallego et al., 2013). Anticoagulation services should aim for a TTR
N70% to maximise beneﬁts and minimise risk of complications in pa-
tients receiving VKA (Wan et al., 2008).5.2. Non-vitamin K Antagonist Oral Antagonists (NOACs)
For over 60 years, VKAswere the only available agents for long-term
oral anticoagulation. They have revolutionised management of AF but
they do have shortcomings. These include a slow onset of action, vari-
able dose requirement that reﬂect, at least in part, common polymor-
phisms inﬂuencing the pharmacokinetics and pharmacodynamics of
VKAs, variations in dietary vitamin K intake, andmultiple drug–drug in-
teractions (De Caterina et al., 2013). These limitations have restricted
the use of warfarin and have led to the development of NOACs.
Currently usedNOACs fall into 2major classes, the oral direct throm-
bin inhibitors (eg. dabigatran) and oral factor Xa inhibitors (e.g.
rivaroxaban, apixaban, edoxaban) (Lip & Lane, 2015a). Routine mea-
surement of the anticoagulant effect of the NOACS is not necessary be-
cause their pharmacokinetic and pharmacodynamic characteristics are
predictable and the therapeutic window is sufﬁciently large to allow
ﬁxed dose administration without the need for routine monitoring of
response (Table 3) (Hankey, 2014).
Four large multicentre Phase III, randomised clinical trials (RE-LY
(Connolly et al., 2009), ROCKET-AF (Patel et al., 2011), ARISTOTLE
(Granger et al., 2011), ENGAGE-AF (Giugliano et al., 2013)) have com-
pared the NOACs against warfarin for stroke prevention in AF. In RE-
LY and ENGAGEAF, two doses of dabigatran and edoxaban, respectively,
were compared with warfarin in a 3 arm trial design (Skjøth et al.,
2014). Dabigatran was administered, in a blinded fashion, in capsules
containing either 110 mg or 150 mg of the drug (Connolly et al.,
2009). In ENGAGE-AF, the high-dose edoxaban group received 60 mg,
and the low-dose group 30 mg (Giugliano et al., 2013). In the
ROCKET-AF trial, which was a 2-arm trial, patients were randomly
assigned to receive either ﬁxed-dose rivaroxaban (20 mg daily with a
dose adjustment to 15 mg daily in patients with a creatinine clearance
of 30 to 49 ml per minute) or adjusted-dose warfarin (Patel et al.,
2011). In ARISTOTLE trial, warfarin was compared to apixaban 5-mg
bid, in a two-arm trial; however, there was a dose adjustment where
2.5-mg bid was used in a patient with two or more of the following
criteria: age ≥ 80 years, a body weight b 60 kg, or serum creatinine
level of 133 μmol/L or higher (Granger et al., 2011). All four NOACs
were at least non-inferior to warfarin regarding prevention of stroke
and systemic thromboembolism and risk of major bleeding and they
consistently caused less intracranial bleeding than warfarin.
In a recent meta-analysis of the four trials (Ruff et al., 2014), 42,411
participants received aNOAC and 29,272 participants receivedwarfarin.
NOACs signiﬁcantly reduced stroke or SE events by 19% compared with
warfarin (RR 0.81, 95% CI 0.73–0.91, p b 0.0001), which was mainly
driven by a reduction in haemorrhagic stroke (RR 0.49, 95% CI 0.38–
0.64, p b 0.0001). NOACs also signiﬁcantly reduced all-cause mortality
(RR 0.90, 0.85–0.95, p = 0.0003) and intracranial haemorrhage (RR
0.48, 95% CI 0.39–0.59; p b 0.0001), but increased gastrointestinal bleed-
ing (RR 1.25, 95% 1.01–1.55, p=0.04). No heterogeneitywere noted for
stroke or systemic embolic events in important subgroups, but there
was a greater relative reduction inmajor bleedingwith new oral antico-
agulants when the centre-based time in therapeutic rangewas less than66% thanwhen itwas 66%ormore (RR 0.69, 95% CI 0.59–0.81 vs RR 0.93,
95% CI 0.76–1.13, p for interaction 0.022).
Low-dose NOACs regimens tested in the trials above showed similar
overall reductions in stroke or systemic thromboembolic events to war-
farin (RR 1.03, 95% CI 0.84–1.27, p = 0.74), and a more favourable
bleeding proﬁle (RR 0.65, 95% CI 0.43–1.00, p = 0.05), but signiﬁcantly
more ischaemic strokes (RR 1.28, 95% CI 1.02–1.60, p = 0.045). Low
dose regimens might be an appealing option for frail patients or for
those who have a high risk for bleeding with full-dose anticoagulation
(Ruff et al., 2014).
Among patients with AF who are at high risk for stroke and for
whom VKA therapy is unsuitable or refused by patients, apixaban
substantially reduced the risk of stroke, as compared with aspirin,
with no signiﬁcant increase in the risk of major bleeding or intracra-
nial bleeding (Connolly et al., 2011). No head-to-head comparisons
of NOACs have been done and comparisons of NOACs based on the
results of large randomised trials of NOACs versus warfarin are prob-
lematic due to differences in the participants CHADS2 score, TTR and
rates of stroke and systemic embolism and haemorrhage in the war-
farin arms of the trials. Predetermined subgroup and post hoc analy-
ses, as well as meta-analyses, have examined the risk and beneﬁts of
NOACs in different patient subgroups. These analyses can be helpful
in guiding NOAC choices in challenging clinical situations (Table 4)
(Shields and Lip, 2015).
Rivaroxaban has a half-life of 5–9 h, however the daily dose for pa-
tients with CrCl N 50 ml/min is 20 mg OD. Pharmacokinetic data from
870 patients with acute DVT in phase II studies found that for the
same total daily doses, the peak plasma concentration was approxi-
mately 20% higher and the trough concentration was approximately
60% lower with the use of once-daily compared with twice-daily regi-
men (Bauersachs et al., 2010). However because the concentration pa-
rameters substantially overlapped with the two regimens, once-daily
dosing should not expose patients to a greater risk of bleeding at the
peak plasma concentration, or a higher risk of thrombogenesis at the
trough plasma concentration compared with the twice-daily dosing
(Mueck et al., 2011).
Given the short half-lives of the NOACs, patients should be
counselled that missing even a single dose might compromise
thromboprophylaxis, and NOACs should not be used in patients with
poor adherence to medication. In addition, NOACs have not been evalu-
ated in patients with severe renal impairment [i.e., creatinine clearance
(CrCl) b 15 mL/min], in patients with valvular AF or malignancy
(Heidbuchel et al., 2015). The CrCl should be assessed before initiating
anticoagulation and at least annually thereafter and at least every
6 months in patients with an eGFR b60 mL/min (Hart et al., 2013).6. Cost Effectiveness of NOACs
Cost effectiveness of theNOACs has been assessed in various studies.
Despite the higher drug costs, rivaroxaban and dabigatran reduce over-
all medical costs compared to warfarin, unless the TTR for warfarin is
above 65% and 70%, respectively. Apixaban has been estimated to re-
duce medical costs compared to warfarin throughout a TTR range of
30–90%) (Amin et al., 2014).
In the United Kingdom, NICE has concluded that the NOACs are all
cost effective and be available to National Health Service (NHS) patients
within their licenced indications. Patients who might particularly
beneﬁt from NOACs include those who cannot take VKAs, have
persistently poor TTR (e.g., b65%) and those taking aspirin for stroke
prevention for whom a NOAC may be an option (Supporting local
implementation of NICE guidance on use of the novel (non-Vitamin K
antagonist) oral anticoagulants in non-valvular atrial ﬁbrillation,
2015). A large reduction in medical cost was mainly driven by reduc-
tions in the risks of major bleedings with the NOACs (Krejczy et al.,
2015).
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A decision to advise OAC should be based upon the individual risks
for stroke and other thromboembolic events and bleeding, with estima-
tion of resultant net clinical beneﬁt (NCB) of treatment.Whilst there are
variousways to deﬁneNCB, it ismost commonly estimatedbybalancing
the risk of ischemic stroke without OAC against the risk of intracranial
haemorrhage with OAC (Lip et al., 2015).
NCB is clearly in favour of OAC in patients with CHADS2 score ≥ 1 or
CHA2DS2-VASc score ≥ 2. NCB is positive or neutral for VKA therapy in
patients with ≥1 stroke risk factors (i.e. CHA2DS2-VASc score ≥ 1). Re-
gardless of HAS-BLED score, there is negative NCB for OAC in patients
with ‘truly low risk’ (i.e., CHA2DS2-VASc score 0) (Olesen et al., 2011b).
NCB analyses from recent randomised trials as well as modelling
analyses applying the clinical trial data to patient cohorts all show a pos-
itive NCB for the NOACs vs warfarin, aspirin or no treatment. Indeed,
one analysis estimated that the use of NOACs has lowered the threshold
for starting OAC is an ischaemic stroke rate of 0.9%/year (Eckman et al.,
2011). In onemodelling analysiswith CHA2DS2-VASc=1, apixaban and
both doses of dabigatran (110mg and 150mg bid) have a positive NCB.
In patients with CHA2DS2-VASc ≥ 2, all three analysed NOACs
(dabigatran, rivaroxaban and apixaban) had NCB superior to warfarin,
regardless of risk of bleeding as determined by HAS-BLED score
(Banerjee et al., 2012b; Blann et al., 2015).
8. Practical Considerations for Oral Anticoagulants
When choosing themost appropriate OAC for a given patient, physi-
cian should be fully aware of the drug pharmacology, the trial results,
stroke and bleeding risk proﬁle and the patient's preferences (Potpara
and Lip, 2013). Common clinical and demographic factors can inﬂuence
the quality of oral anticoagulation,making it feasible to identify patients
who are less likely to keepwithin the target INR range. These factors are
incorporated into the simple SAMe-TT2R2 score (Table 5) [sex female,
age b 60 years, medical history (more than two comorbidities), treat-
ment (interacting drugs, e.g. amiodarone for rhythm control), tobacco
use (doubled), race non-Caucasian (doubled)]. The SAMe-TT2R2 score
is predictive of patients likely to have poor INR control (as reﬂected by
poor TTR) and could aid decision making in management of AF byTable 1
Event rates (95% CI) of hospital admission and death due to thromboembolism per 100
person years [based on Olesen et al. (2011a)].
Score/risk category 1 year's follow-up 5 years' follow-up
CHA2DS2-VASc
0 0.78 (0.58 to 1.04) 0.69 (0.59 to 0.81)
1 2.01 (1.70 to 2.36) 1.51 (1.37 to 1.67)
2 3.71 (3.36 to 4.09) 3.01 (2.83 to 3.20)
3 5.92 (5.53 to 6.34) 4.41 (4.21 to 4.61)
4 9.27 (8.71 to 9.86) 6.69 (6.41 to 6.99)
5 15.26 (14.35 to 16.24) 10.42 (9.95 to 10.91)
6 19.74 (18.21 to 21.41) 12.85 (12.07 to 13.69)
7 21.50 (18.75 to 24.64) 13.92 (12.49 to 15.51)
8 22.38 (16.29 to 30.76) 14.07 (10.80 to 18.33)
9 23.64 (10.62 to 52.61) 16.08 (8.04 to 32.15)
CHA2DS2-VASc
Low risk (0) 0.78 (0.58 to 1.04) 0.69 (0.59 to 0.81)
Intermediate risk (Ball et al.,
2013)
2.01 (1.70 to 2.36) 1.51 (1.37 to 1.67)
High risk (Camm et al., 2012a;
Kirchhof et al., 2011; Pisters
et al., 2012; Camm et al., 2010;
Choudhury and Lip, 2004; Lip &
Lane, 2015a; Fibrillation and
Group, 2007; Banerjee et al.,
2012a)
8.82 (8.55 to 9.09) 6.01 (5.88 to 6.14)
CHA2DS2-VASc: C, congestive heart failure, H, hypertension, A2, age at least 75 years, D, di-
abetes, S2, previous stroke, TIA, or systemic embolism, V, vascular disease, A, age 65
through 74 years, Sc, sex category female sex.identifying patients who would do well on VKAs (SAMe-TT2R2 score
0–2) or, conversely, those who are likely to require NOAC or some
intervention(s) to help them achieve acceptable anticoagulation control
(ie, SAMe-TT2R2 score N 2) (Apostolakis et al., 2013d).
A number or retrospective cohorts have independently validated the
SAMe-TT2R2 score (Abumuaileq et al., 2015; Roldán et al., 2015; Gallego
et al., 2014; Poli et al., 2014). In one prospective multicentre study per-
formed in Spain on thenationwide sample of patientswithnon-valvular
AF receiving VKA the SAMe-TT2R2 score had a signiﬁcant, although
moderate, ability to identify patients with a good anticoagulation con-
trol as well as modest values of sensitivity and speciﬁcity (Ruiz-Ortiz
et al., 2015). In a large French cohort, a high SAMe-TT2R2 score trans-
lates into labile INRs, which in turn is associated with a greater risk of
thromboembolism, mortality and severe bleeding (Lip et al., 2014a).
Thus, SAMe-TT2R2 is an acceptable predictor of the quality of
anticoagulation control in patients with non-valvular AF on VKAs, and
its predictive ability can be improved if integrated with the physician's
judgement, which accounts for the overall circumstances of the patient.
9. Ethnicity and Thromboprophylaxis in Atrial Fibrillation
Intracerebral or subarachnoid haemorrhage (ICH) accounts for 15–
20% of strokes in white subjects (Thrift et al., 2001) and ICH rates in
Asians are substantially higher (20–30%) among people of black
(Broderick et al., 1992), Hispanic (Sacco et al., 1998) or Asian origin
(Klatsky et al., 2005; Hu et al., 1992). Non-white patients, especially
those of Asian origin, experienced substantially higher risk for
warfarin-related ICH compared with whites (Shen et al., 2007). An im-
portant consideration is whether all races/ethnicities require the same
anticoagulation intensity with VKA. NOACs have overcome that issue
and fared even better in Asian patients compare with non-Asians. A re-
cent meta-analysis (Wang et al., 2015) of the large phase III NOAC trials
found that standard doses of NOACs were more effective than warfarin
in the reduction of systemic embolism and haemorrhagic stroke in
Asians; also, the absolute risk reduction in major bleeding by
standard-dose NOACs was generally greater in Asians than in non-
Asian patients.
10. Management of Anticoagulation Related Bleeding
Mild bleedings (such as epistaxis and ecchymosis) can be managed
conservatively with the application of local haemostatic measures. In
patients experiencing a moderate to severe bleeding, the type and loca-
tion of bleeding should be considered. For example, gastrointestinal
bleedings, which occur into an open cavity are rarely fatal. In case of a
severe/life-threatening bleeding, such as bleeding into a critical organ
(particularly intracranial haemorrhage) or bleeding that causes haemo-
dynamic instability, all antithrombotic therapy should be stopped im-
mediately. Patients should be managed with maximum supportive
measures and early referral for procedural or surgical intervention if ap-
propriate (Weitz and Pollack, 2015).
For VKAs, replacement is necessary to correct the low levels of fac-
tors II, VII, IX and X. This can be achieved by using prothrombin complex
concentrate (PCC), preferably, or fresh frozen plasma (FFP) (Tran et al.,
2013). Administration of vitamin K, whilst a speciﬁc antidote for the
VKAdrugs, takes N12 h towork, and supportivemeasures are still need-
ed in the interim.
The NOACs have a moderate half-life (ranging from 5 to 9 h for
rivaroxaban to 12–17 h for dabigatran) and in the event of a NOAC over-
dose supportive measures should be initiated and continued until the
drug concentrations drop. In addition, non-speciﬁc reversal agents
(such as PCC or recombinant factor VIIa) can be considered, but this is
based on limited clinical evidence (Weitz and Pollack, 2015).
Dabigatran can be partially removed by dialysis in the case of life-
threatening bleeding or renal failure. However, dialysis may be time
consuming to be practical in a life-threatening situation and can only
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inhibitors are highly bound to plasma proteins; therefore, dialysis is not
expected to reduce their plasma levels.11. Speciﬁc Antidotes to NOACs
Idarucizumab, a monoclonal antibody fragment, binds dabigatran
with an afﬁnity that is 350 times higher than with thrombin and neu-
tralises dabigatran activity. The prospective RE-VERSE AD study cohort
assessed the efﬁcacy and safety of idarucizumab for reversal of the anti-
coagulant effects of dabigatran in patients who presented with serious
bleeding or who required urgent surgery or intervention (Pollack
et al., 2015a). Idarucizumab rapidly and completely reversed the antico-
agulant effect of dabigatran in 98% of the patients. Only 1 of the 90 pa-
tients (1%) had a thrombotic event within 72 h after idarucizumab
administration, and antithrombotic therapy had not been reinitiated
in that patient (Pollack et al., 2015b). Idarucizumab received its ﬁrst ap-
proval for clinical practise in theUSA inOctober 2015 for use in adult pa-
tients treated with dabigatran etexilate when rapid reversal of its
anticoagulant effects is required for emergency surgery/urgent proce-
dures or in life-threatening or uncontrolled bleeding.
Andexanet alpha is a modiﬁed recombinant FXa lacking enzymatic
activity which is currently in an earlier stage of development for
neutralisation of direct and indirect FXa inhibitors. A phase 3 study to
evaluate the effect of andexanet in bleeding patients receiving FXa-
inhibitors started in 2015. In addition, a small molecule ciraparantag
has entered phase I clinical trials. Ciraparantag binds non-covalently
to anticoagulants, inhibiting the anticoagulant effects of low molecular
weight heparins, fondaparinux, oral FXa inhibitors and dabigatran
(Greinacher et al., 2015).Table 2
Recommendations of guidelines.
Guidelines Risk factors Tr
AHA/ACC/HRS 2014 (January et al.,
2014)
CHA2DS2-VASc score
≥2 V
1 N
0 N
NICE 2014 (Atrial ﬁbrillation:
management | Guidance and
guidelines | NICE, 2015)
CHA2DS2-VASc score
For males ≥ 1 or females ≥ 2 V
For males 0 or females 1 N
CCS 2014 (Verma et al., 2014) CHADS2 score
Identify those aged ≥65 y and CHADS2 score
risk factors
V
No risk factors (ie, age b 65 y with no
CHADS2 risk factors or vascular disease)
N
No risk factors, ie, age b 65 y with no
CHADS2 risk factors with vascular disease
A
ACCP 2012 (You et al., 2012) CHADS2 score
0 plus additional non-CHADS2 risk factors
(eg, age 65–74 y, woman, and vascular
disease)
W
≥1 W
No risk factors N
ESC 2012 (Camm et al., 2012a) CHA2DS2-VASc
For males ≥ 1 or females ≥ 2 V
th
re
For males 0 or females 1 N
Abbreviations: AHA/ACC/HRS: American Heart Association/American College of Cardiology/Hea
CCS: Canadian Cardiovascular Society, NICE: National Institute for Health and Care Excellence,
abetes, S2, previous stroke, TIA, or systemic embolism, V, vascular disease, A, age 65 through 74
at least 75 years, D, diabetes, and S2, previous stroke, transient ischemic attack (TIA), or system
oral anticoagulation, TTR: time in therapeutic range.12. Restarting Oral Anticoagulation After Ischaemic or
Haemorrhagic Stroke and Major Gastrointestinal Bleeding
The observed incidence of early (within 14 days) recurrent ischae-
mic stroke is 8% (Berge, 2000). Early initiation of anticoagulation may
thus be effective in preventing early recurrence. This potential beneﬁt
must, however be balanced with the potential risk for ICH.
Observational data suggest that independent predictors for symp-
tomatic haemorrhagic transformation of ischaemic stroke are large in-
farct, previous haemorrhagic stroke and low platelet count (Lee et al.,
2010). For patients without high-risk features, the risk for symptomatic
ICH whilst undergoing anticoagulation therapy is 1.5% within 14 days
(Lee et al., 2010). In the European Atrial Fibrillation Trial (EAFT),
which enrolled patients with TIA or minor stroke, oral anticoagulation
was found to be effective in a protocol that initiated warfarin within
14 days of symptom onset in approximately half of the patients
([European atrial ﬁbrillation trial (EAFT), 2015). In most trials of
NOACs, the study drug could not be started within 7 to 14 days of a
stroke event (Connolly et al., 2009; Granger et al., 2011; Patel et al.,
2011). However, the RE-LY trial delayed eligibility for 6 months after a
severe stroke (Diener et al., 2010). Recent guidelines from the
American Heart Association/American Stroke Association advise that
formost patientswith a stroke or TIA in the setting of AF, it is reasonable
to initiate OACwithin 14 days after the onset of neurological symptoms;
however, in the presence of high risk for haemorrhagic conversion, it is
reasonable to delay initiation of OAC beyond 14 days (Kernan et al.,
2014).
ICH occurs in up to 1% of patients on OAC per year and it is the most
feared and devastating complication of this treatment (Lansberg et al.,
2012). AF patients who experience an ICH are at very high risk of ische-
mic stroke and mortality if they are not on antithrombotic therapyeatment
KAs or NOACs
othing, aspirin or NOAC
o OAC
KAs or NOACs
othing
KAs or NOACs
othing
spirin
arfarin or dabigatran
arfarin or dabigatran
othing
KAs if TTR N 70% or NOACs. Antiplatelet therapy with aspirin-clopidogrel combination
erapy or, less effectively, aspirin monotherapy is recommended only when patients
fuse any form of OAC
othing
rt Rhythm Society, ESC: European Society of Cardiology, ACCP: American College of Chest,
CHA2DS2-VASc: C, congestive heart failure, H, hypertension, A2,age at least 75 years, D, di-
years, Sc, sex category female sex. CHADS2: C, congestive heart failure, hypertension, A, age
ic embolism; VKAs: vitamin K antagonists, NOAC: non-vitamin K oral anticoagulant, OAC:
Table 3
Pharmacokinetic properties and other proﬁle features of non-vitamin K oral antagonists.
Drug Dabigatran Rivaroxaban Apixaban Edoxaban
Mechanism of
action
Direct thrombin inhibitor Direct factor Xa inhibitor Direct factor Xa inhibitor Direct factor Xa
inhibitor
Fixed dose Twice daily Once daily Twice daily Once daily
Half-life (h) 12–17 5–9 9–12 8–11
Time to peak
effect (h)
2 2–3 1–2 1–2
Renal elimination 80% 33% 25% 35%
Drug interactions Strong P-gp inhibitors and
inducers
Strong CYP3A4 inducers, strong inhibitors of both
CYP3A4 and P-gp
Strong inhibitors and inducers of CYP3A4
and P-gp
Strong P-gp inhibitors
Coagulation assay aPTT, dTT Ecarin clotting
time
PT Chromogenic anti-Xa assay Chromogenic anti-Xa assay Chromogenic anti-Xa
assay
Abbreviations: P-gp—permeability glycoprotein, aPTT—activated partial thromboplastin time, dTT—dilute thrombin time, PT—prothrombin time.
Table 4
Suggested patient groups in which speciﬁc non-VKA oral anticoagulants (NOACs) may be
relatively advantageous.
Individual patient
groups and
characteristics
NOACs with
characteristics
beneﬁcial to
target
group
Elderly patients Consider comorbidities and agents with
lower extracranial haemorrhage among
elderly (age N 75)
Apixaban
Edoxaban
Renal impairment
(45 ml/min N CrCl N
15 ml/min)
Consider agents with lower haemorrhagic
complications in moderate to severe renal
impairment
Apixaban
Previous GI
haemorrhage
Consider agents with no increased risk of
GI haemorrhage
Apixaban
Dabigatran
110 mg
High bleeding risk
(HAS-BLED ≥ 3)
Consider agents with lower incidence of
extracranial haemorrhage
Apixaban
Dabigatran
110 mg
Edoxaban
Recurrent stroke
despite well
managed VKA
Consider agent with demonstrable beneﬁt
in reducing both ischaemic AND
haemorrhagic stroke
Dabigatran
150 mg
Preference for low
pill burden
Consider once daily formulations Edoxaban
Rivaroxaban
Abbreviations: CrCl creatinine clearance, HAS-BLED: H, hypertension, A, abnormal renal
and liver function, S, stroke, B, bleeding tendency, L, labile INRs, E, elderly, D, drugs. GI gas-
trointestinal, VKA vitamin K antagonist.
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clude increasing age, concomitant use of aspirin or nonsteroidal anti-
inﬂammatory drugs, uncontrolled hypertension, spontaneous ICH,
lobar bleed and cerebral amyloid angiopathy (Nielsen et al., 2015;
Qureshi et al., 2001). Patients with lobar haemorrhage, microbleeds or
cerebral amyloid angiopathy remain at higher risk for anticoagulant-
related ICH recurrence than thromboembolic events and may be best
managed without anticoagulants. Patients with deep hemispheric ICH
and a baseline risk of ischemic stroke N6.5% per year, that corresponds
to CHA2DS2-VASc ≥5, may have net beneﬁt from restarting
anticoagulation. To date, a reasonable recommendation regarding time
from stroke to resumption of anticoagulation therapy would be 8–
10 weeks (Lansberg et al., 2012; Paciaroni and Agnelli, 2014).
Reported rates of major bleeding among individuals with AF taking
oral VKAs vary widely ranging from 1.3% to 7.2% per year. This variabil-
ity of the values reﬂects the differences in the studies patient popula-
tions and the methodology employed (Lip et al., 2011). Most bleeding
events are gastrointestinal bleedings (Hansen et al., 2010).
The largest published cohort study was contacted in Denmark and
included 4602 patients with AF discharged from hospital after gastroin-
testinal bleeding while receiving antithrombotic treatment. Among pa-
tients surviving the ﬁrst 90 days after gastrointestinal bleeding,
restarting single treatment with oral anticoagulation was associated
with the lowest risk of all-cause mortality and thromboembolism. In
one medium size retrospective cohort study analysis of patients who
developed major gastrointestinal bleedings whilst taking warfarin and
later had evidence of the bleeding resolution, restarting warfarin was
independently associated with decreased mortality (adjusted hazard
ratio 0.66, 95% CI 0.55–0.80, p b 0.0001) (Qureshi et al., 2014). In a
smaller observational cohort study resuming OAC after hospitalisation
for gastrointestinal bleedings was associated with a signiﬁcantly de-
creased adjusted risk of major thromboembolic events over 90 days,
without a signiﬁcantly increased risk of recurrent gastrointestinal
bleedings (Sengupta et al., 2015). These data support the recommenda-
tion that OAC should be continued after an episode of gastrointestinal
bleedings whenever possible.
13. Antiplatelet Therapy
Antiplatelet therapy is inferior to adjusted dose warfarin for preven-
tion of stroke by approximately 40%. Aspirin does not lower the absolute
risk of stroke, particularly in patients who are more than 75 years old
(J. Stroke Cerebrovasc. Dis., 1993). Different aspirin doses appear to
have similar effect in AF (Hart et al., 2007) and the risk ofmajor bleeding
or intracranial haemorrhage with aspirin is similar to that of OAC, espe-
cially in the elderly (Cammet al., 2012b). Based onmeta-analysis of four
trials aspirin does not signiﬁcantly reduce all-cause mortality in AF
(Hart et al., 1999).
For themajority of patientswith AF, aspirin has limited role in stroke
prevention. Nonetheless, aspirinmay be considered in AF patients in the
early stages following acute coronary syndrome, and after angioplasty,in combination with an oral anticoagulant and clopidogrel, as appropri-
ate. Clopidogrel monotherapy is probably inferior to warfarin mono-
therapy in the prevention of ischemic stroke and bears a risk of
bleeding similar to that of aspirin monotherapy (Hansen et al., 2010).
Notably, aspirin combined with clopidogrel shows only modest beneﬁt
in stroke prevention compared with aspirin monotherapy in patients
with AF who refuse oral anticoagulant drugs (Lip, 2011). The use of an-
tiplatelet therapy for stroke prevention in AF should be limited to the
minority of patients who refuse any form of OAC (Camm et al., 2012b).
14. Oral Anticoagulation in Severe Renal Impairment (Creatinine
Clearance b 15 ml/min)
The overall prevalence of AF is approximately 15% among
haemodialysis patients (Hart et al., 2013). In a large cohort study,
among patients with AF, non-end stage chronic kidney disease and dis-
ease requiring renal replacement therapy were both associated with in-
creased risks of stroke or systemic embolism and bleeding. Warfarin
therapy was associated with a signiﬁcant reduction in the risk of stroke
or systemic embolism among patients with chronic kidney disease but
the risk of bleeding among such patients was signiﬁcantly increased
(Hart et al., 2013). Thus, the net clinical effect of warfarin treatment in
chronic kidney disease requires careful assessment on individual basis
(Olesen et al., 2012).
Table 5
Recommended risk assessment tools for stroke risk, bleeding risk and successful vitamin K antagonist-based anticoagulation in patients with atrial ﬁbrillation.
Risk of stroke Risk of bleeding Likelihood TTR ≥ 70%
(choosing between VKA or NOAC)
CHA2DS2VASc score (Lip, 2010) HAS-BLED score (Pisters et al., 2010) SAMe-TT2 R2 score (Apostolakis et al., 2013d)
Condition or characteristic Points Condition or characteristic Points Deﬁnition Points
Congestive heart failure 1 Hypertension 1 Sex (female) 1
Hypertension 1 Abnormal renal and liver function (1 point
each)
1 or 2 Age (b60 y) 1
Age ≥ 75 y 2 Stroke 1 Medical historya 1
Diabetes mellitus 1 Bleeding tendency/predisposition
(anaemia)
1 Treatment (interacting drugs, eg, amiodarone for rhythm
control)
1
Stroke/TIA/SE 2 Labile INRs (eg, TTR b 60%) 1 Tobacco use (within 2 y) 2
Vascular disease (prior ACS, PAD, or aortic
plaque)
1 Elderly (eg, age N 65 y, frail condition) 1 Race (not white) 2
Age 65–74 y 1 Drugsbc or alcohol excess (1 point each) 1 or 2 8
Sex category (ie, female sex)a 1 9
Maximum score 9
Abbreviations: VKA—vitaminK antagonist, NOAC—non-vitaminK oral antagonist, TTR—time in therapeutic range, TIA—transient ischaemic attack, SE—systemic embolism, ACS—acute cor-
onary syndrome, PAD—peripheral arterial disease, INR—international normalised ratio.
a Two of the following: hypertension, diabetesmellitus, coronary artery disease ormyocardial infarctions, peripheral artery disease, congestive heart failure, previous stroke, pulmonary
disease, or hepatic or renal disease.
b Concomitant antiplatelet drugs, Steroids, non-steroidal anti-inﬂammatory drugs.
c Counts only in the presence of another risk factor.
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edwith a signiﬁcantly higher risk of AF than peritoneal dialysis. Progres-
sive cardiac enlargement was more frequent in haemodialysis patients
despite adequate blood pressure control thus predisposing to AF occur-
rence and persistence (Abbott et al., 2003).
Patients with severe renal impairment were excluded from all
major NOACs trials (Camm et al., 2012a). All NOACs are partly or pre-
dominantly excreted by the kidneys, but only dabigatran is removed
by dialysis. There is uncertainty regarding appropriate NOAC dosing
in patients with end stage renal disease on dialysis. In a recent study
that was conducted in US, dabigatran and rivaroxaban in patients on
hemodialysis was associated with a higher risk of hospitalisation or
death from bleeding when compared with warfarin (Chan et al.,
2015).
15. Oral Anticoagulation and Percutaneous Coronary Intervention
In patients on OAC undergoing PCI, peri-procedural anticoagulation
should bemanaged depending on the setting in which PCI is performed
(i.e. elective vs ACS). In general, radial artery vascular access is prefera-
ble to reduce risk of bleeding (Rubboli et al., 2014). In patients with sta-
ble CAD and AF undergoing PCI at low bleeding risk (HAS-BLED 0-2),
triple antithrombotic therapy (OAC, aspirin 75–100 mg daily and
clopidogrel 75 mg daily) should be given for a minimum of 4 weeks
(and no longer than 6 months) after PCI, following by dual therapy
withOAC (either aNOAC or a VKA) and clopidogrel 75mg/day (or alter-
natively, aspirin 75–100 mg/day) for up to 12 months. In patients with
myocardial infarction and AF at low risk of bleeding (HAS-BLED 0–2),
the initial use of triple therapy (OAC, aspirin, and clopidogrel) should
be considered for 6 months following PCI irrespective of stent type;
this should be followed by long-term therapy (up to 12 months) with
OAC and clopidogrel 75 mg/day. In patients with ACS and AF at high
risk of bleeding (HAS-BLED ≥ 3), the initial use of triple therapy (OAC,
aspirin, and clopidogrel) should be considered for 4 weeks following
PCI irrespective of stent type; this should be followed by long-term
therapy (up to 12 months) with OAC and a single antiplatelet drug
(preferably clopidogrel 75 mg/day, or as an alternative, aspirin 75–
100 mg/day). Long-term antithrombotic therapy (beyond 12 months)
should be with OAC alone (VKA or a NOAC).
The open-label, randomised, controlled WOEST trial (Dewilde et al.,
2013) suggested that patients undergoing PCI and are on treatment
with warfarin (only two-thirds had AF) should be managed by acombination of warfarin and clopidogrel for 1 year post PCI and then
with warfarin indeﬁnitely. This was based on the ﬁnding that the use
of clopidogrel without aspirin was associated with a signiﬁcant reduc-
tion in bleeding complications and no increase in the rate of thrombotic
events. However, the HAS-BLED score and the CHA2DS2-VASc score
were not used for decision making in the trial. Also, a placebo was not
used instead of aspirin in the double-therapy group. Other limitations
of this trial have been discussed (PubMed — NCBI, 2015a).
In patients receiving VKA, the TTR should be maintained above 70%
to avoid excess in stroke or haemorrhage. The lower tested dose of the
NOACs for stroke prevention is advisable, when used in combination
with antiplatelet therapy. The combination of OACs with prasugrel or
ticagrelor should be avoided (Lip et al., 2014b).16. Oral Anticoagulation and Cardioversion
Based on guidelines, in patients with AF of duration more 48 h (or
AF of unknown duration) oral anticoagulation should be given for at
least 3 weeks prior to cardioversion, or transoesophageal echocardi-
ography should be performed to rule out left atrial thrombi (Camm
et al., 2010).
Observational data from the RE-LY trial showed a comparatively
low stroke rate related to cardioversion in patients treated with ei-
ther dabigatran and VKAs (Nagarakanti et al., 2011). Analysis of
data from the ARISTOTLE trial showed that patients undergoing
cardioversions being managed with either apixaban or warfarin
had no thromboembolic events within the ﬁrst 90 days (Flaker
et al., 2014). Likewise, there was no difference in the ROCKET-AF
trial in the number of strokes or systemic embolisms betweenwarfa-
rin and rivaroxaban following electrical or pharmacological cardio-
version (Piccini et al., 2013).
The pre-procedural time before cardioversion is usually not delayed
with NOACs, as is commonwith VKAs due to non-therapeutic INRs (un-
less there is a compliance issue). It is mandatory to explicitly ask the pa-
tient about adherence over the previous 3 weeks and to document the
answer in the history notes. If compliance with NOAC has been con-
ﬁrmed, cardioversion seems acceptably safe. Transoesophageal echo-
cardiogram should be considered if there is doubt about compliance.
In patients with stroke risk factors or at high risk of recurrence, OAC
should be continued long-term, whether with a VKA or a NOAC
(Heidbuchel et al., 2015; Lip & Lane, 2015a).
35C. Voukalis et al. / EBioMedicine 4 (2016) 26–3917. Catheter Ablation and Anticoagulation in Atrial Fibrillation
Catheter ablation should be reserved for patients with AF who re-
main symptomatic despite optimal medical therapy (Camm et al.,
2010). A medium size randomised study showed that performing cath-
eter ablation of AF without warfarin discontinuation and with a thera-
peutic INR in patients at high risk for stroke signiﬁcantly reduces the
occurrence of periprocedural stroke/TIA and minor bleeding complica-
tions (Di Biase et al., 2014). The VENTURE-AF is the ﬁrst randomised
prospective comparative trial of an uninterrupted NOAC (Rivaroxaban)
vs. VKA therapy in patients with AF undergoing catheter ablation. In pa-
tients undergoing catheter ablation for AF, the use of uninterrupted oral
rivaroxaban was feasible and event rates were similar to those for
uninterrupted VKA therapy (Cappato et al., 2015). More trials are un-
derway to deﬁne the role of dabigatran [RE-CIRCUIT, DAPPAR-AF
(NCT01468155) and ODIn-AF (PubMed — NCBI, 2015b)] around the
time of ablation procedures.
18. Should Bridging Therapy Be Used or Not?
Bridging anticoagulation is deﬁned as administration of a short-
acting anticoagulant (low molecular weight heparin or unfractionated
heparin) during interruption of VKA therapywhen the INR is not within
a therapeutic range (Douketis et al., 2012). Use of bridging
anticoagulation was associated with signiﬁcantly higher overall rates
of bleeding and the data do not support routine use of bridging in
anticoagulated patients with non-valvular AF (Steinberg et al., 2015;
Douketis et al., 2015).
Post-procedural heparin use should be reserved for patientswith the
highest thromboembolic risk (e.g., patients with mitral or multiple me-
chanical heart valves or prior stroke) (Schulman et al., 2015). Given the
rapid onset and offset of action of NOACs, no bridging therapy is re-
quired for the majority of interventions, although this is dependent
upon balancing the risks of stroke/thromboembolism vs. bleeding in in-
dividual cases and the HAS-BLED score can to assist the decision. Fol-
lowing surgery, NOACs can be restarted as soon as effective
haemostasis has been achieved, and the anticoagulant effect will be ev-
ident within a few hours after the ﬁrst dose (Camm et al., 2012b).
19. Left Atrial Appendage Occlusion
The left atrial appendage (LAA) is considered the main (but not the
only) site of thrombi formation in the heart in AF. Minimally invasive
epicardial and interventional trans-septal techniques have been devel-
oped for occlusion of the LAA oriﬁce to reduce the stroke risk (Camm
et al., 2012b). The two trials assessed the LAA occlusion devicesTable 6
Comparison of the PREVAIL and PROTECT studies.
Study PRE
201
Group Inte
Number of patients 269
CHADS2 score mean ± standard deviation (range) 2.6
Age, years mean ± standard deviation (range) 74.0
Implant success 95.1
All 7-day procedural complications 4.5%
Ischemic stroke 1.9%
18-
All-cause mortality 2.6%
18-
Primary efﬁcacy event rate (after the ﬁrst 7 days from randomisation) for
prevention of stroke and Systemic embolism
Non
a Percutaneous closure of the LAA by use of WATCHMAN device.
b Warfarin for the duration of the study (target international normalised ratio [INR] betwee(PROTECT-AF, PREVAIL) and showed that the devices were non-
inferior to warfarin for ischemic stroke prevention or systemic embo-
lism during 7 days post-procedure, although non-inferiority was not
achieved for overall efﬁcacy (Table 6) (Holmes et al., 2009; Holmes
et al., 2014). Current consensus is that LAA occlusionmay be considered
in patients with a high stroke risk and contraindications for long-term
OAC (Atrial ﬁbrillation: management | Guidance and guidelines | NICE,
2015).
20. Thrombolysis in AF Patients Receiving Oral Anticoagulation
Patients with AF who experience acute ischaemic stroke should be
considered for urgent thrombolytic therapy to restore perfusion and
function of the ischemic brain. However, effective anticoagulation pres-
ent at the time of reperfusion is a contraindication for thrombolysis be-
cause of the possibility of increased risk of symptomatic haemorrhage
(De Keyser et al., 2007). Therefore, current guidelines recommend
against using the intravenous recombinant tissue-type plasminogen ac-
tivator alteplase in patients with acute ischemic stroke who have an in-
ternational normalised ratio (INR) N 1.7 (Xian et al., 2012). The possible
risk of thrombolysis in patients given NOACs remains unclear.
Point-of-care coagulation tests are urgently warranted for manage-
ment of acute stroke, especially in patients pre-treated with NOAC and
who are eligible for intravenous thrombolysis. A patient taking one of
the NOACs who experiences an acute ischemic stroke should not be
considered a candidate for thrombolysis unless his/her clinical history
and the results of laboratory tests reliably indicate the absence of an an-
ticoagulant effect, or until at least two half-lives have elapsed since the
most recent dose in patientswith normal renal function and coagulation
tests are normal (Diener et al., 2013). In a patient taking dabigatran, a
quick and simple test could be an activated partial thromboplastin test
(aPTT), and for rivaroxaban, a calibrated dilute prothrombin time
(Heidbuchel et al., 2015).
21. Conclusion
Oral anticoagulation is the cornerstone for stroke prevention in AF.
Recent advances in AF related stroke and bleeding risk stratiﬁcation fa-
cilitate an essential shift in clinical decision-making regarding the use of
oral anticoagulant therapy in non-valvular AF. However there are still
clinical scenarios, like valvular AF and end stage renal failure associated
with AF,whereNOACshave a limited role and the use of VKAs is needed.
There is insufﬁcient evidence to recommendoneNOAC over another, al-
though some patient characteristics, drug compliance, tolerability and
cost may be important considerations in the choice of agent. The devel-
opment of speciﬁc NOAC antidotes marks a step forward in addressingVAIL (Holmes et al.,
4)
PROTECT (Holmes et al.,
2009)
rventiona Controlb Interventiona Controlb
138 463 244
± 1.0 (1.0, 6.0) 2.2 ± 1.2 (1.0, 6.0)
± 7.4 (50.0, 94.0) 71.7 ± 8.8 (46.0, 95.0)
% 90.9%
8.7%
month
0.7%
18-month
15/694 · 6
Events/
patient-years
6/372 · 3
Events/
patient-years
month
2.2%
18-month
21/708 · 4
Events/
patient-years
18/374 · 9
Events/
patient-years
-inferior to warfarin Non-inferior to warfarin
n 2 · 0 to 3 · 0).
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agents for the NOACs would improve the conﬁdence of clinicians and
patients in the NOACs and promote adequate anticoagulation in these
patients.
22. Outstanding Questions
Many questions still need to be answered regarding the use and the
safety of the NOACs. Should patients with stable TTR be switched to a
NOAC? Will poor adherence have a greater negative impact with the
NOACs than with VKAs? What is the optimal management of patients
with ﬂuctuating renal function? Will individualised NOAC dose adjust-
ment lead to greater efﬁcacy and safety? Will poor adherence have a
greater negative impact with the NOACs than with VKAs?
To optimise the effectiveness of NOACs in routine practise across a
wide spectrum of patients, further data are needed to answer these
questions and improve conﬁdence of both physicians and patients
when using these drugs.
23. Search Strategy
Data for this reviewwere identiﬁed by searches of PubMed using the
search terms: atrial ﬁbrillation, thromboembolism, stroke risk, risk
stratiﬁcation, oral anticoagulation, warfarin, aspirin, non-Vitamin K
oral anticoagulant, net clinical beneﬁt and thromboprophylaxis. Our
searchwas conducted for articles up to 31 October 2015 andwe focused
on primary published research articles and systematic reviews, as well
as on clinical trials complemented by large observational cohorts.
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